Evidence map›Paper›PMID 33605379›Full record

ArticleRevista da Sociedade Brasileira de Medicina Tropical2021

Electrocardiographic effect of artemisinin-piperaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine treatment in falciparum malaria patients.

Wanting Wu, Chenguang Lu, Yuan Liang, Hongying Zhang, Changsheng Deng, Qi Wang, Qin Xu, Bo Tan, Chongjun Zhou, Jianping Song

Open access · diamondAbstract read
In one paragraph

Article in Revista da Sociedade Brasileira de Medicina Tropical, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Wanting WuGuangzhou University of Chinese Medicine, Artemisinin Research Center, Guangzhou, Guangdong, People's Republic of China.
Chenguang LuGuangzhou University of Chinese Medicine, Artemisinin Research Center, Guangzhou, Guangdong, People's Republic of China.
Yuan LiangGuangzhou University of Chinese Medicine, Artemisinin Research Center, Guangzhou, Guangdong, People's Republic of China.
Hongying ZhangGuangzhou University of Chinese Medicine, Artemisinin Research Center, Guangzhou, Guangdong, People's Republic of China.
Changsheng DengGuangzhou University of Chinese Medicine, Artemisinin Research Center, Guangzhou, Guangdong, People's Republic of China.
Qi WangGuangzhou University of Chinese Medicine, Artemisinin Research Center, Guangzhou, Guangdong, People's Republic of China.
Qin XuGuangzhou University of Chinese Medicine, Artemisinin Research Center, Guangzhou, Guangdong, People's Republic of China.
Bo TanGuangzhou University of Chinese Medicine, Institute of Tropical Medicine, Guangzhou, Guangdong, People's Republic of China.
Chongjun ZhouGuangzhou University of Chinese Medicine, Institute of Tropical Medicine, Guangzhou, Guangdong, People's Republic of China.
Jianping SongGuangzhou University of Chinese Medicine, Artemisinin Research Center, Guangzhou, Guangdong, People's Republic of China.ORCID http://orcid.org/0000-0002-5429-0440
Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionArtemisinin-based combination therapy (ACT), such as artemisinin-piperaquine (AP), dihydroartemisinin-piperaquine (DP), and artemether-lumefantrine (AL), is the first-line treatment for malaria in many malaria-endemic areas. However, we lack a detailed evaluation of the cardiotoxicity of these ACTs. This study aimed to analyze the electrocardiographic effects of these three ACTs in malaria patients.

methodsWe analyzed the clinical data of 89 hospitalized patients with falciparum malaria who had received oral doses of three different ACTs. According to the ACTs administered, these patients were divided into three treatment groups: 27 treated with AP (Artequick), 31 with DP (Artekin), and 31 with AL (Coartem). Electrocardiograms and other indicators were recorded before and after the treatment. The QT interval was calculated using Fridericia's formula (QTcF) and Bazett's formula (QTcB).

resultsBoth QTcF and QTcB interval prolongation occurred in all three groups. The incidence of such prolongation between the three groups was not significantly different. The incidence of both moderate and severe prolongation was not significantly different between the three groups. The ΔQTcF and ΔQTcB of the three groups were not significantly different. The intra-group comparison showed significant prolongation of QTcF after AL treatment.

conclusionsClinically recommended doses of DP, AL, and AP may cause QT prolongation in some malaria patients but do not cause torsades de pointes ventricular tachycardia or other arrhythmias.

Indexed as

AntimalarialsArtemisininsMalariaMalaria, FalciparumArtemetherArtemether, Lumefantrine Drug CombinationDrug CombinationsElectrocardiographyHumansPiperazinesQuinolinesAntimalarialsArtemetherArtemether, Lumefantrine Drug CombinationArtemisininsartenimolDrug CombinationspiperaquinePiperazinesQuinolines

Identifiers

PMID33605379
PMCPMC7891559
OpenAlexW3130423800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.